Fintel reports that on July 21, 2023, Morgan Stanley reiterated coverage of Johnson & Johnson (NYSE:JNJ) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 7.71% Upside
As of July 6, 2023, the average one-year price target for Johnson & Johnson is 183.31. The forecasts range from a low of 162.61 to a high of $225.75. The average price target represents an increase of 7.71% from its latest reported closing price of 170.19.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Johnson & Johnson is 98,624MM, an increase of 0.87%. The projected annual non-GAAP EPS is 10.50.
What is the Fund Sentiment?
There are 5182 funds or institutions reporting positions in Johnson & Johnson. This is a decrease of 41 owner(s) or 0.78% in the last quarter. Average portfolio weight of all funds dedicated to JNJ is 1.06%, an increase of 14.57%. Total shares owned by institutions increased in the last three months by 108.79% to 4,209,470K shares. 
The put/call ratio of JNJ is 0.81, indicating a bullish outlook.
What are Other Shareholders Doing?
Bank Julius Baer & Co. Ltd, Zurich holds 2,255,083K shares representing 86.78% ownership of the company. In it's prior filing, the firm reported owning 2,267K shares, representing an increase of 99.90%. The firm increased its portfolio allocation in JNJ by 0.44% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 80,616K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 79,472K shares, representing an increase of 1.42%. The firm decreased its portfolio allocation in JNJ by 17.81% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 61,006K shares representing 2.35% ownership of the company. In it's prior filing, the firm reported owning 60,440K shares, representing an increase of 0.93%. The firm decreased its portfolio allocation in JNJ by 17.86% over the last quarter.
Geode Capital Management holds 48,708K shares representing 1.87% ownership of the company. In it's prior filing, the firm reported owning 47,959K shares, representing an increase of 1.54%. The firm decreased its portfolio allocation in JNJ by 17.58% over the last quarter.
Northern Trust holds 33,475K shares representing 1.29% ownership of the company. In it's prior filing, the firm reported owning 33,757K shares, representing a decrease of 0.84%. The firm decreased its portfolio allocation in JNJ by 17.80% over the last quarter.
Johnson & Johnson Background Information
(This description is provided by the company.)
Johnson & Johnson believes good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, Johnson & Johnson has aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, Johnson & Johnson is committed to using its reach and size for good. Johnson & Johnson strives to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Johnson & Johnson is blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Additional reading:
- JOHNSON & JOHNSON REPORTS 2023 SECOND-QUARTER RESULTS:
- SECOND QUARTER
- SEPARATION AGREEMENT by and between JOHNSON & JOHNSON KENVUE INC. Dated as of May 3, 2023
- TAX MATTERS AGREEMENT by and between JOHNSON & JOHNSON KENVUE INC. Dated as of May 3, 2023
- EMPLOYEE MATTERS AGREEMENT by and between JOHNSON & JOHNSON KENVUE INC. Dated as of May 3, 2023
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
